All In Biotech

Drug Trial Radar · NCT06948955

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Cogent Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Apr 29, 2025

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

The purpose of this expanded access program (EAP) is to provide investigational bezuclastinib so that it can be coadministered with sunitinib to patients with a diagnosis of gastrointestinal stromal tumors (GIST) with no comparable or satisfactory alternative therapy options. The combination of bezuclastinib and sunitinib provides broad inhibition of all primary and secondary KIT mutations that commonly occur in GIST.

Conditions

  • Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Interventions

  • BezuclastinibDrug

    Drug: Bezuclastinib

  • SunitinibDrug

    Drug: Sunitinib (locally sourced)

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona · Available

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Available

  • UCLA Department of Medicine- Hematology/Oncology

    Los Angeles, California · Available

  • University of Colorado

    Aurora, Colorado · Available

  • Smillow Cancer Hospital - Yale New Haven Health

    New Haven, Connecticut · Available

  • Mayo Clinic

    Jacksonville, Florida · Available

  • Orlando Health

    Orlando, Florida · Available

  • Northwestern Memorial Hospital

    Chicago, Illinois · Available

  • The University of Chicago Medical Center

    Chicago, Illinois · Available

  • Johns Hopkins University

    Baltimore, Maryland · Available

  • Dana Farber Cancer Institute (DFCI)

    Boston, Massachusetts · Available

  • Karmanos Cancer Institute

    Detroit, Michigan · Available

  • Mayo Clinic

    Rochester, Minnesota · Available

  • Roswell Park Cancer Institute

    Buffalo, New York · Available

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Available

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Available

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Available

  • Taylor Cancer Research Center

    Maumee, Ohio · Available

  • Oregon Health and Sciences University

    Portland, Oregon · Available

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Available

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Available

  • MD Anderson Cancer Center

    Houston, Texas · Available

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Available

  • Shenandoah Oncology

    Winchester, Virginia · Available

  • Shenandoah Oncology

    Winchester, Virginia · Available

  • Northwest Medical Specialties

    Tacoma, Washington · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.